BioXcel Therapeutics (BTAI) Misses Q1 EPS by 129c

BioXcel Therapeutics (NASDAQ: BTAI) reported Q1 EPS of ($1.50), $1.29 worse than the analyst estimate of ($0.21). Revenue for the quarter came in at $168 thousand versus the consensus estimate of $400 thousand.

For earnings history and earnings-related data on BioXcel Therapeutics (BTAI) click here.

You May Also Be Interested In

• Crude Inventory Rose 2.97 Million Barrels Last Week - EIA
• Intuit (INTU) call put ratio 1 call to 1.5 puts as share price down 1.3%
• Vuzix signs distribution deal with CommsPlus for Australia and Pacific